U.S. markets closed

Concert Pharmaceuticals, Inc. (CNCE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.7700-0.1100 (-3.82%)
At close: 4:00PM EDT
2.8100 +0.04 (+1.44%)
After hours: 06:25PM EDT

Concert Pharmaceuticals, Inc.

65 Hayden Avenue
Suite 3000N
Lexington, MA 02421
United States
781 860 0045

Full Time Employees71

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard H. Aldrich M.B.A., MbaCo-Founder & Chairman80kN/A1954
Dr. Roger D. TungCo-Founder, CEO, Pres & Exec. Director914.16kN/A1960
Ms. Nancy StuartChief Operating OfficerN/AN/A1958
Dr. James V. CassellaChief Devel. Officer691.36kN/A1955
Mr. Marc A. BeckerCFO & Principal Accounting OfficerN/AN/A1972
Ms. Justine E. KoenigsbergSr. VP of Corp. Communications and Investor RelationsN/AN/AN/A
Mr. Jeffrey A. MunsieChief Legal Officer & Corp. Sec.N/AN/A1977
Dr. Nabil Uddin Pharm.D.VP of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Concert Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.